eMERGE delivers the insights needed to support confident preclinical decisions in RNA therapeutics.
Contact us
Integrative analytics for IVT RNA characterization and quality control
eMERGE is a sequencing-first platform that delivers actionable insights into RNA therapeutic potency, stability, and safety. Generate the data needed to support effective vaccine and therapeutic quality control while reducing development timelines.
Contact usOverview
Use:
IVT RNA QC and characterization
Typical samples:
IVT mRNA, saRNA/srRNA, circular RNA
Reveal RNA quality with sequencing
Ready to obtain advanced analytics? Contact us today.
Get actionable insightsDiscuss
Our scientific and project management teams meet with you to review your challenges and goals.
Plan
We develop a customized project proposal that is tailored for your specific goals.
Analyze
Our team of RNA experts processes your samples and delivers a comprehensive, actionable insights report.
Reveal RNA
quality
The following examples highlight how eMERGE generates actionable insights into key RNA quality attributes. Contact us to learn more about our comprehensive characterization capabilities.
Locate and quantify dsRNA impurities
IVT errors can generate double-stranded RNA (dsRNA) that activates the innate immune system. Locating the sequence origins of dsRNA, however, is challenging. We have developed a unique, next-generation sequencing-based approach to
- Quantify dsRNA including lengths below antibody detection limits
- Identify where IVT runoff begins and ends
- Evaluate the effects of different manufacturing optimizations or base changes on dsRNA production
This plot shows dsRNA levels across an RNA sequence, with regions contributing to dsRNA formation highlighted. Line thickness and color indicate each base’s relative contribution to dsRNA generation.
Determine RNA structure in LNPs and cells
RNA structure is critical for stability. RNA structure is critical for stability, yet computational predictions can be inaccurate in the context of LNPs or the cellular environment. With our proprietary approach we:
- Directly measure RNA structure in LNPs
- Evaluate secondary structure in cells
- Determine changes in structure during drug product formulation
RNA structures can change with different LNP formulations, potentially leading to changes in storage stability. Data was generated in partnership with Acuitas Therapeutics.
Evaluate ribosome dynamics
Efficient translation is critical for RNA efficacy, yet ribosome stalls and frameshifts can limit protein output. We use empirical data from target cell types to:
- Locate ribosome stalls and optimize sequences to improve translation
- Measure translation over time to identify optimal candidates for therapeutic efficacy
- Select optimal codons that are cell- and tissue-specific
Identification of ribosome pause sites along an IVT mRNA
Comprehensive solutions for RNA success
eMERGE uses multiple sequencing-based approaches to fully characterize RNA therapeutic quality. These analytics can be paired with our AI design and manufacturing capabilities to deliver complete preclinical drug development support.